Sign in

    Samuel Lee

    Biotech Equity Research Associate at Mizuho Financial Group, Inc.

    Samuel Lee is a Biotech Equity Research Associate at Mizuho Financial Group, specializing in the analysis of investment opportunities within the biotechnology sector. He covers a range of biotech companies and brings strong expertise in both financial modeling and sector-specific research, though formal performance track records and rankings are not publicly available. Samuel began his career focusing on accounting analytics, with previous roles including Accounting Analyst at Mizuho Financial Group and Assistant Vice President at Morgan Stanley, highlighting his broad experience in financial data analysis before specializing in biotech research. He holds professional credentials relating to financial analysis and equity research, drawing on substantial sector knowledge in both investment and biotechnology.

    Samuel Lee's questions to Amylyx Pharmaceuticals (AMLX) leadership

    Samuel Lee's questions to Amylyx Pharmaceuticals (AMLX) leadership • Q2 2025

    Question

    Samuel Lee, on for Greg Svanihan, inquired about potential patient compliance issues with a daily injectable like Avexatide and asked for feedback from the physician community following the recent ENDO conference.

    Answer

    Co-CEO & Co-Founder Josh Cohen noted that past trials showed near-100% compliance and market research indicates patients are not concerned, viewing it favorably compared to frequent finger sticks. Chief Medical Officer Dr. Camille Bedrosian added that physician feedback from ENDO was very positive, with growing awareness and excitement about a potential treatment.

    Ask Fintool Equity Research AI